Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
2,188
Views
1
CrossRef citations to date
0
Altmetric
Cardiovascular

Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis

Carina Blomström Lundqvista Department of Cardiology, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
,
Sara Själanderb Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
,
Luis A. Garcia Rodriguezc Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, SpainORCID Iconhttps://orcid.org/0000-0003-0837-2709
ORCID Icon,
Örjan Åkerborgd Wickenstones Ltd., Carlow, Ireland
,
Guanyi Jind Wickenstones Ltd., Carlow, Ireland
,
Amrit Caleyachettyd Wickenstones Ltd., Carlow, IrelandORCID Iconhttps://orcid.org/0000-0003-4968-4952
ORCID Icon,
Maria Huelsebecke Bayer AG, Berlin, Germany
,
Kevin Bowrinf Bayer Plc, Reading, UKORCID Iconhttps://orcid.org/0000-0001-9165-471X
ORCID Icon,
Bernhard Schaefere Bayer AG, Berlin, Germany
,
Hovsep Mahdessiang Bayer AB, Stockholm, Sweden
,
Lucas Hofmeistere Bayer AG, Berlin, Germany
&
Lars-Åke Levinh Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, SwedenCorrespondence[email protected]
 show all
Pages 1085-1091 | Received 19 Jul 2022, Accepted 22 Aug 2022, Published online: 07 Sep 2022

References

  • Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–847.
  • Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014;45(9):2599–2605.
  • Lanitis T, Kongnakorn T, Jacobson L, et al. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. Thromb Res. 2014;134(2):278–287.
  • Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
  • Patel MR, Mahaffey KW, Garg J, the ROCKET AF Steering Committee, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
  • Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
  • January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2019;74(1):104–132.
  • Jackevicius CA, Tsadok MA, Essebag V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017;103(17):1331–1338.
  • Ozaki AF, Choi AS, Le QT, et al. Real-World adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circul Cardiovasc Qual Outcome. 2020;13(3):e005969.
  • (TLV) TDaPBA. Ändring i Tandvårds- och läkemedelsförmånsverkets allmänna råd (TLVAR 2003:2) om ekonomiska utvärderingar 2017.
  • Bowrin K, Briere JB, Levy P, et al. Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK. J Mark Access Health Policy. 2020;8(1):1782164.
  • Bank EC. Swedish krona (SEK) Frankfurt: European Central Bank; 2021 [cited 2021 Aug 20]. Available from: https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-sek.en.html.
  • Komen JJ, Heerdink ER, Klungel OH, et al. Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Eur Heart J Cardiovasc Pharmacother. 2021;7(Fi1):f72–f80.
  • Komen JJ, Forslund T, Mantel-Teeuwisse AK, et al. Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. Eur Heart J Cardiovasc Pharmacother. 2021;7(1):3–10.
  • Pennlert J, Overholser R, Asplund K, et al. Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke. 2017;48(2):314–320.
  • Aronsson M, Svennberg E, Rosenqvist M, et al. et al. Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis Europace 2017;19(10):1650–1656.
  • Luengo-Fernandez R, Gray AM, Bull L, For the Oxford Vascular Study, et al. Quality of life after TIA and stroke: ten-year results of the oxford vascular study. Neurology. 2013;81(18):1588–1595.
  • Lindgren P, Glader EL, Jönsson B. Utility loss and indirect costs after stroke in Sweden. Eur J Cardiovasc Prev Rehabil. 2008;15(2):230–233.
  • World Health Organisation. Global Health Observatory data repository; 2020. Available from: https://apps.who.int/gho/data/?theme=main&vid=61600.
  • Centralbyrån S. Konsumentprisindex (KPI). 2021. Available from: https://www.scb.se/hitta-statistik/statistik-efter-amne/priser-och-konsumtion/konsumentprisindex/konsumentprisindex-kpi.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.